留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

纳米羟基磷灰石及其复合材料作为药物载体的研究进展

卢英 荀晓伟 杨志伟 罗红林 万怡灶 左桂福

卢英, 荀晓伟, 杨志伟, 等. 纳米羟基磷灰石及其复合材料作为药物载体的研究进展[J]. 复合材料学报, 2020, 37(12): 2953-2965. doi: 10.13801/j.cnki.fhclxb.20200814.002
引用本文: 卢英, 荀晓伟, 杨志伟, 等. 纳米羟基磷灰石及其复合材料作为药物载体的研究进展[J]. 复合材料学报, 2020, 37(12): 2953-2965. doi: 10.13801/j.cnki.fhclxb.20200814.002
LU Ying, XUN Xiaowei, YANG Zhiwei, et al. Research progress of nano-hydroxyapatite and its composite materials as drug carriers[J]. Acta Materiae Compositae Sinica, 2020, 37(12): 2953-2965. doi: 10.13801/j.cnki.fhclxb.20200814.002
Citation: LU Ying, XUN Xiaowei, YANG Zhiwei, et al. Research progress of nano-hydroxyapatite and its composite materials as drug carriers[J]. Acta Materiae Compositae Sinica, 2020, 37(12): 2953-2965. doi: 10.13801/j.cnki.fhclxb.20200814.002

纳米羟基磷灰石及其复合材料作为药物载体的研究进展

doi: 10.13801/j.cnki.fhclxb.20200814.002
基金项目: 国家自然科学基金 (51662009;31660264);江西省教育厅科学技术研究项目(GJJ180348)
详细信息
    通讯作者:

    左桂福,博士,教授,硕士生导师,研究方向为生物复合材料  E-mail:zuoguifu@163.com

  • 中图分类号: TB332;TQ4460

Research progress of nano-hydroxyapatite and its composite materials as drug carriers

  • 摘要: 纳米羟基磷灰石(HAp)具有良好的生物活性和药物吸附性,是一种理想的无机药物载体。本文从生物安全性、抗肿瘤活性和药物吸附性三个方面阐述了纳米HAp的载药特性,探讨了其微观形貌对载药性能的影响,对载药纳米HAp复合材料的分类、制备及载药和释药性能进行了系统综述,旨在为纳米HAp及其复合材料在药物载体领域的应用提供理论基础。

     

  • 图  1  羟基磷灰石(HAp)的晶体结构[28]

    Figure  1.  Crystal structure of hydroxyapatite (HAp)[28]

    图  2  载药纳米HAp的几种典型形貌

    Figure  2.  Several typical morphologies of drug-loaded HAp ((a) Nanorods[33]; (b) Needle-like shape[34]; (c) Lamellar[35]; (d) Hollow microsphere[36]; (e) Hollow ellipsoidal capsules[37]; (f) Nanotubes[38])

    图  3  实心纳米载体(a)和空心多孔纳米载体(b)的载药模型[47]

    Figure  3.  Schemes of drug loading for solid nanoparticles (a) and hollow porous nanoparticles (b)[47]

    图  4  不同形貌的HAp/甲氨蝶呤(MTX)杂化物的制备过程和细胞吞噬示意图[49]

    Figure  4.  Schematic diagram of preparation process and cell phagocytosis of HAp/methotrexate (MTX) complexes with different morphologies[49]

    图  5  层片状HAp(LHAp)/5-FU复合物的制备流程图[50] (a)和LHAp/DNA的酶解保护和酸解释放示意图[51] (b)

    Figure  5.  Preparation flow chart of lamellar HAp (LHAp)/5-FU complex[50] (a), illustration of DNA protection provided by lamellar HAp and DNA release in acidic conditions[51] (b)

    5-FU—5-fluorouracil

    图  6  HAp@氧化石墨烯(GO)的合成、载药过程、内吞过程和协同治疗癌细胞的示意图[52]

    Figure  6.  Schematic illustration of the synthesis of HAp@graphene oxide (GO), the drug loading process, the endocytosis process and the proposed mechanism of synergistic therapy against cancer cells[52]

    DOX—Doxorubicin; NIR—Night-time ozone profile

    图  7  介孔SiO2纳米颗粒(MSNs)/HAp复合材料的设计、降解和药物储存/释放过程的示意图[53]

    Figure  7.  A schematic representation of the design of mesoporous SiO2 nanoparticle (MSNs)/HAp composites, subsequent degradation and drug storage/release process[53]

    图  8  CS和CS/LHAp复合水凝胶的反复电刺激质量变化曲线[57]

    Figure  8.  Mass changes of composite hydrogels under cyclic on–off switching electrostimulation[57]

    图  9  DOX@LHAp/聚乳酸羟基乙酸(PLGA)复合材料的药物释放示意图[60] (a)、DOX@聚丙烯酸(PAA)-介孔羟基磷灰石纳米颗粒(MHAPNs)的制备流程图和细胞内pH响应药物释放示意图[62] (b)

    Figure  9.  Schematic diagram of the drug release of DOX@LHAp/polylactic acid (PLGA) composite[60] (a), schematic illustration of the preparation of DOX@polyacrylic acid (PAA)-mesoporous hydroxyapatite nanoparticles (MHAPNs) and the intracellular pH-responsive drug delivery system[62] (b)

    图  10  GO/HAp/壳聚糖(CS)/针状HAp纳米晶对顺铂(CDDP)复合材料治疗骨肉瘤的示意图[65]

    Figure  10.  Schematic diagram of GO/HAp/chitosan (CS)/cisplatin (CDDP) composite material for the treatment of osteosarcoma[65]

    MG 63 cells—Human osteosarcoma cells

  • [1] 孙夏囡, 何文, 闫顺璞, 等. 载药纳米羟基磷灰石的研究[J]. 山东轻工业学院学报, 2009, 23(1):44-48.

    SUN X N, HE W, YAN S P, et al. Study on the drug-loaded nano-hydroxyapatite[J]. Journal of Shandong Institute of Light Industry,2009,23(1):44-48(in Chinese).
    [2] RAUSCHMANNA M A, WICHELHAUS T A, STIRNAL V, et al. Nanocrystalline hydroxyapatite and calcium sulphate as biodegradable composite carrier material for local delivery of antibiotics in bone infections[J]. Biomaterials,2005,26(15):2677-2684. doi: 10.1016/j.biomaterials.2004.06.045
    [3] LEGEROS R Z. Calcium phosphate-based osteoinductive materials[J]. Chemical Reviews,2008,108(11):4742-4753. doi: 10.1021/cr800427g
    [4] 陈杰, 王广妮, 严永刚, 等. 可注射nano HA/PAG/CS复合材料的制备与表征[J]. 复合材料学报, 2013, 30(1):96-102.

    CHEN J, WANG G N, YAN Y G, et al. Preparation and characterization of injectable composite of nano HA/PAG/CS[J]. Acta Materiae Compositae Sinica,2013,30(1):96-102(in Chinese).
    [5] ROUSSLIIE A V. Ultrastructural evidence in vitro of osteoclast-induced degradation of calcium phosphate ceramic by simultaneous resorption and phagocytosis mechanisms[J]. Histology & Histopathology,2001,16(1):37-44.
    [6] LEGEROS R Z. In vitro interactions of bone marrow cells with carbonate and fluoride containing apatites[J]. Key Engineering Materials,2001,192-195:347-350.
    [7] GONDA Y, IOKU K, SHIBATA Y, et al. Stimulatory effect of hydrothermally synthesized biodegradable hydroxyapatite granules on osteogenesis and direct association with osteoclasts[J]. Biomaterials,2009,30(26):4390-4400. doi: 10.1016/j.biomaterials.2009.05.002
    [8] 许艳慧, 李四群, 李志安. 纳米羟基磷灰石复合材料的研究-纳米羟基磷灰石的细胞毒性[J]. 实用口腔医学杂志, 2004, 20(2):147-150. doi: 10.3969/j.issn.1001-3733.2004.02.005

    XU Y H, LI S Q, LI Z A. Development of nanometer hydroxyapatite complex materials-cytotoxicity test of nano-hydroxyapatite by MTT-assay[J]. Journal of Practical Stomatology,2004,20(2):147-150(in Chinese). doi: 10.3969/j.issn.1001-3733.2004.02.005
    [9] AOKI H, AOKI H, KUTSUNO T, et al. An in vivo study on the reaction of hydroxyapatite-sol injected into blood[J]. Journal of Materials Science: Materials in Medicine,2000,11(2):67-72. doi: 10.1023/A:1008993814033
    [10] MONDAL S, PAL U, DEY A. Natural origin hydroxyapatite scaffold as potential bone tissue engineering substitute[J]. Ceramics International,2016,42(16):18338-18346. doi: 10.1016/j.ceramint.2016.08.165
    [11] HUANG J, BEST S M, BONFIELD W, et al. In vitro assessment of the biological response to nano-sized hydroxyapatite[J]. Journal of Materials Science: Materials in Medicine,2004,15(4):441-445. doi: 10.1023/B:JMSM.0000021117.67205.cf
    [12] PILLIAR R M, FILIAGG M J, WELLS J D, et al. Porous calcium polyphosphate scaffolds for bone substitute applications-in vitro characterization[J]. Biomaterials,2001,22(9):963-972. doi: 10.1016/S0142-9612(00)00261-1
    [13] LI Y, SHI H S, LI G. Current application of hydroxyapatite nanoparticles in tumor field[J]. Journal of Clinical Rehabilitative Tissue Engineering Research,2008,12(32):6393-6396.
    [14] 王志新, 刘莹, 孔祥波, 等. 纳米羟基磷灰石对人源性泌尿系肿瘤细胞增殖的影响[J]. 中国老年学杂志, 2007, 27(23):2276-2277. doi: 10.3969/j.issn.1005-9202.2007.23.005

    WANG Z X, LIU Y, KONG X B, et al. The effect of nano-hydroxyapatite on the proliferation of human urinary tumor cells[J]. Chinese Journal of Gerontology,2007,27(23):2276-2277(in Chinese). doi: 10.3969/j.issn.1005-9202.2007.23.005
    [15] 张士成, 李世普, 陈芳. 磷灰石超微粉对癌细胞作用的初步研究[J]. 武汉工业大学学报, 1996, 18(1):5-8.

    ZHANG S C, LI S P, CHENG F. Studies on effects of apatite ultrafinepowder on cancer cells[J]. Journal of Wuhan University of Technology,1996,18(1):5-8(in Chinese).
    [16] CHU S H, FENG D F, MA Y B, et al. Hydroxyapatite nanoparticles inhibit the growth of human glioma cells in vitro and in vivo[J]. International Journal of Nanomedicine,2012,7:3659-3666.
    [17] ZHANG K, ZHOU Y, XIAO C, et al. Application of hydroxyapatite nanoparticles in tumor-associated bone segmental defect[J]. Science Advances,2019,5(8):1-16.
    [18] 冯凌云, 阎玉华, 陈闻杰, 等. 羟基磷灰石溶胶对W-256癌肉瘤细胞内钙离子浓度及细胞形态结构的影响[J]. 中国生物医学工程学报, 1998, 17(4):374-377.

    FENG L Y, YAN Y H, CHEN W J, et al. Effect of HAp-sol on Ca2+ concentration of W-256 sarcoma cells and morphology of cells[J]. Chinese Journal of Biomedical Engineering,1998,17(4):374-377(in Chinese).
    [19] 张建平, 夏清华. 羟基磷灰石超微粉对肿瘤细胞系Walker256的DNA损伤[J]. 实用癌症杂志, 1997, 12(4):245-247.

    ZHANG J P, XIA Q H. The role of hydroxyapatite ultrafinepower in DNA damage of the tumer cell line Walker256[J]. The Practical Journal of Cancer,1997,12(4):245-247(in Chinese).
    [20] CHEN J, LI S P. The influence of nano-apatite on c-myc and p53 gene in the hepatocellular carcinoma[J]. Journal of Wuhan University of Technology-Materials Science,2005,20(2):57-59. doi: 10.1007/BF02838489
    [21] 夏清华, 陈道林, 林华, 等. HASM对W-256细胞系DNA含量及细胞周期的影响[J]. 武汉工业大学学报, 1999, 21(2):5-6.

    XIA Q H, CHEN D L, LIN H, et al. Effects of hydroxyapatite supermicromist on DNA content and cell cycle of W-256 sarcoma cell[J]. Journal of Wuhan University of Technology,1999,21(2):5-6(in Chinese).
    [22] 曹献英, 李世普, 闫玉华, 等. 纳米羟基磷灰石的表征及其对肝癌抑制作用的研究[J]. 硅酸盐通报, 2015, 22(4):21-24.

    CHAO X Y, LI S P, YAN Y H, et al. Study on characterizition of nano-HAP and its inhibition on human hepatocelluar carcinoma cell lins[J]. Bulletin of The Chinese Ceramic Society,2015,22(4):21-24(in Chinese).
    [23] 陈筠, 曹献英, 韩颖超, 等. 纳米磷灰石对肝癌癌基因表达的影响[J]. 武汉理工大学学报, 2005, 27(9):29-31. doi: 10.3321/j.issn:1671-4431.2005.09.010

    CHEN J, CAO X Y, HAN Y C, et al. Affection of nano-apatite on the expression of the oncogene and anti-oncogene in the hepatocellular carcinoma cells[J]. Journal of Wuhan University of Technology,2005,27(9):29-31(in Chinese). doi: 10.3321/j.issn:1671-4431.2005.09.010
    [24] LI S P. The effect of nano-apatite on the expression of telomerase gene of human hepatocellular carcinoma cells[J]. Journal of Wuhan University of Technology,2004,20(12):315-317.
    [25] JIN J, ZUO G F, XIONG G Y, et al. The inhibition of lamellar hydroxyapatite and lamellar magnetic hydroxyapatite on the migration and adhesion of breast cancer cells[J]. Journal of Materials Science: Materials in Medicine,2014,25(4):1025-1031. doi: 10.1007/s10856-013-5126-8
    [26] 赵欣, 王德平. 纳米羟基磷灰石作为药物载体材料的研究进展[J]. 材料导报, 2010, 24(12):116-120.

    ZHAO X, WANG D P. The research development of nano-hydroxyapatite as a drug carrier[J]. Materials Reports,2010,24(12):116-120(in Chinese).
    [27] KAY M I, YOUNG R A, POSNER A S. Crystal structure of hydroxyapatite[J]. Nature,1964,204(4963):1050-1052. doi: 10.1038/2041050a0
    [28] 邹雪艳, 赵彦保, 张治军. 纳米羟基磷灰石的合成方法研究进展[J]. 化学研究, 2019, 20(4):404-410.

    ZOU X Y, ZHAO Y B, ZHANG Z Z. Progress in the synthesis method of hydroxyapatite[J]. Chemical Research,2019,20(4):404-410(in Chinese).
    [29] 陈庆榆, 朱融融, 张蕤, 等. 纳米羟基磷灰石对两种药物的载药性能研究[J]. 复旦学报, 2009, 48(3):386-390.

    CHEN Q Y, ZHU R R, ZHANG R, et al. Preparation and characterization of nano-hydroxyapatite as carrier of two drugs[J]. Journal of Fudan University,2009,48(3):386-390(in Chinese).
    [30] ZHOU H L, WU T, DONG X L, et al. Adsorption mechanism of BMP-7 on hydroxyapatite (001) surfaces[J]. Biochemical and Biophysical Research Communications,2007,361(1):91-96. doi: 10.1016/j.bbrc.2007.06.169
    [31] PAN H H, TAO X H, XU H R, et al. Adsorption processes of Gly and Glu amino acids on hydroxyapatite surfaces at the atomic level[J]. Langmuir,2007,23(17):8972-8981. doi: 10.1021/la700567r
    [32] SZCZEŚ A, HOLYSZ L, CHIBOWSKI E. Synthesis of hydroxyapatite for biomedical applications[J]. Advances in Colloid and Interface Science,2017,249:321-330. doi: 10.1016/j.cis.2017.04.007
    [33] ZHANG C M, LI C X, HUANG S S, et al. Self-activated luminescent and mesoporous strontium hydroxyapatite nanorods for drug delivery[J]. Biomaterials,2010,31(12):3374-3383. doi: 10.1016/j.biomaterials.2010.01.044
    [34] SANTOS C, TURIEL S, GOMES P S, et al. Vascular biosafety of commercial hydroxyapatite particles: Discrepancy between blood compatibility assays and endothelial cell behavior[J]. Journal of Nanobiotechnology,2018,16(1):27. doi: 10.1186/s12951-018-0357-y
    [35] WAN Y Z, WU C Q, ZUO G F, et al. Controlled template synthesis of lamellar hydroxyapatite nanoplates as a potential carrier for gene delivery[J]. Materials Chemistry and Physics,2015,156:238-246. doi: 10.1016/j.matchemphys.2015.03.011
    [36] ZHAO Q, ZHANG D Q, SUN R X, et al. Adsorption behavior of drugs on hydroxyapatite with different morphologies: A combined experimental and molecular dynamics simulation study[J]. Ceramics International,2019,45(15):19522-19527. doi: 10.1016/j.ceramint.2019.06.068
    [37] MA M Y, ZHU Y J, LI L, et al. Nanostructured porous hollow ellipsoidal capsules of hydroxyapatite and calcium silicate: preparation and application in drug delivery[J]. Journal of Materials Chemistry,2008,18(23):2722-2727. doi: 10.1039/b800389k
    [38] GUO X K, YU L, CHEN L H, et al. Organoamine-assisted biomimetic synthesis of faceted hexagonal hydroxyapatite nanotubes with prominent stimulation activity for osteoblast proliferation[J]. Journal of Materials Chemistry B,2014,2(13):1760-1763. doi: 10.1039/C3TB21652G
    [39] HAIDER A, HAIDER S, HAN S S, et al. Recent advances in the synthesis, functionalization and biomedical applications of hydroxyapatite: A review[J]. RSC Advances,2017,7(13):7442-7458. doi: 10.1039/C6RA26124H
    [40] MONDAL S, DOROZHKIN S V, PAL U. Recent progress on fabrication and drug delivery applications of nanostructured hydroxyapatite[J]. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology,2018,10(4):1-32.
    [41] 李宾杰, 姚素梅, 李淑莲, 等. 纳米羟基磷灰石的制备及在生物医学上的应用研究进展[J]. 化学研究, 2010, 21(5):90-96. doi: 10.3969/j.issn.1008-1011.2010.05.024

    LI B J, YAO S M, LI S L, et al. Research progress in preparation of nanoscale hydroxyapatite and its application in biomedicine field[J]. Chemical Research,2010,21(5):90-96(in Chinese). doi: 10.3969/j.issn.1008-1011.2010.05.024
    [42] 赵宏霞. 羟基磷灰石微结构调控的研究进展[J]. 功能材料, 2017, 1(48):1047-1055.

    ZHAO H X. Research progress of microstructure regulation for hydroxyapatite[J]. Functional Materials,2017,1(48):1047-1055(in Chinese).
    [43] XU S Y, LONG J D, SIM L, et al. RF plasma sputtering deposition of hydroxyapatite bioceramics: Synthesis, performance, and biocompatibility[J]. Plasma Processes & Polymers,2005,2(5):373-390.
    [44] ZHAO X, NG S, HENG B C, et al. Cytotoxicity of hydroxyapatite nanoparticles is shape and cell dependent[J]. Archives of Toxicology,2013,87(6):1037-1052. doi: 10.1007/s00204-012-0827-1
    [45] GUPTA A S. Role of particle size, shape, and stiffness in design of intravascular drug delivery systems: Insights from computations, experiments, and nature[J]. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology,2015,8(2):255-270.
    [46] MANIYA N H, PATEL S R, MURTHY Z V P. Electrochemical preparation of microstructured porous silicon layers for drug delivery applications[J]. Superlattices & Microstructures,2013,55:144-150.
    [47] 刘安琪, 陈建峰, 李雪光, 等. 空心多孔纳米载体负载药物的药量分布研究[J]. 高校化学工程学报, 2007, 21(5):832-837. doi: 10.3321/j.issn:1003-9015.2007.05.018

    LIU A Q, CHEN J F, LI X G, et al. Study of drug loading distribution of porous hollow nano-carriers[J]. Journal of Chemical Engineering of Chinese Universities,2007,21(5):832-837(in Chinese). doi: 10.3321/j.issn:1003-9015.2007.05.018
    [48] PALAZZO B, IAFISCO M, LAFORGIA M, et al. Biomimetic hydroxyapatite-drug nanocrystals as potential bone substitutes with antitumor drug delivery properties[J]. Advanced Functional Materials,2007,17(13):2180-2188. doi: 10.1002/adfm.200600361
    [49] SUN H N, LIU S S, ZENG X F, et al. Morphology effect of nano-hydroxyapatite as a drug carrier of methotrexate[J]. Journal of Materials Science Materials in Medicine,2017,28(10):158. doi: 10.1007/s10856-017-5978-4
    [50] LUO H L, JI D H, LI C Z, et al. Layered nanohydroxyapatite as a novel nanocarrier for controlled delivery of 5-fluorouracil[J]. International Journal of Pharmaceutics,2016,513(1-2):17-25. doi: 10.1016/j.ijpharm.2016.09.004
    [51] ZUO G F, WAN Y Z, MENG X G, et al. Synthesis and characterization of a lamellar hydroxyapatite/DNA nanohybrid[J]. Materials Chemistry and Physics,2011,126(3):470-475. doi: 10.1016/j.matchemphys.2010.12.060
    [52] SANG R, CHEN M, YANG Y Y, et al. HAp@GO drug delivery vehicle with dual-stimuli-triggered drug release property and efficient synergistic therapy function against cancer[J]. Journal of Biomedical Materials Research Part A,2019,107(10):2296-2309. doi: 10.1002/jbm.a.36738
    [53] HAO X H, HU X X, ZHANG C M, et al. Hybrid mesoporous silica-based drug carrier nanostructures with improved degradability by hydroxyapatite[J]. ACS Nano,2015,9(10):9614-9625. doi: 10.1021/nn507485j
    [54] 胡龙驹, 杨建东. 纳米羟基磷灰石人工骨复合材料载药研究进展[J]. 中国骨与关节损伤杂志, 2013, 28(3):297-299. doi: 10.7531/j.issn.1672-9935.2013.03.053

    HU L J, YANG J D. Research progress on drug loading of nano-hydroxyapatite artificial bone composites[J]. Chinese Journal of Bone and Joint Injury,2013,28(3):297-299(in Chinese). doi: 10.7531/j.issn.1672-9935.2013.03.053
    [55] ZOU Q, LI Y B, ZHANG L, et al. Antibiotic delivery system using nano-hydroxyapatite/chitosan bone cement consisting of berberine[J]. Journal of Biomedical Materials Research Part A,2009,89(4):1108-1117.
    [56] DING Z Z, FAN Z H, HUANG X W, et al. Bioactive natural protein-hydroxyapatite nanocarriers for optimizing osteogenic differentiation of mesenchymal stem cells[J]. Journal of Materials Chemistry B,2016,40(20):3555-3561.
    [57] ZUO G F, WAN Y Z, LIU Z J, et al. Preparation and characterisation of laminated hydroxyapatite/chitosan compo-site hydrogels[J]. Plastics, Rubber and Composites,2013,43(2):71-75.
    [58] MA X Y, DONG X L, ZHANG C Y, et al. Polyglutamic acid-coordinated assembly of hydroxyapatite nanoparticles for synergistic tumor-specific therapy[J]. Nanoscale,2019,11(32):15312-15325. doi: 10.1039/C9NR03176F
    [59] GUO B L, MA P X. Synthetic biodegradable functional polymers for tissue engineering: A brief review[J]. Science China-Chemistry,2014,57(4):490-500. doi: 10.1007/s11426-014-5086-y
    [60] LUO H L, ZHANG Y, YANG Z W, et al. Encapsulating doxorubicin-intercalated lamellar nanohydroxyapatite into PLGA nanofibers for sustained drug release[J]. Current Applied Physics,2019,19(11):1204-1210. doi: 10.1016/j.cap.2019.08.003
    [61] TAI I C, FU Y C, WANG C K, et al. Local delivery of controlled-release simvastatin/PLGA/HAp microspheres enhances bone repair[J]. International Journal of Nanomedicine,2013,8:3895-3904.
    [62] LI D L, XIN H, WU Y D, et al. Preparation of pH-responsive mesoporous hydroxyapatite nanoparticles for intracellular controlled release of an anticancer drug[J]. Biomaterials Science,2016,4(2):272-280. doi: 10.1039/C5BM00228A
    [63] 牛旭锋, 冯庆玲, 王明波, 等. 微囊化壳聚糖/纳米羟基磷灰石/胶原/聚乳酸复合材料[J]. 复合材料学报, 2009, 26(2):143-148. doi: 10.3321/j.issn:1000-3851.2009.02.025

    NIU X F, FENG Q L, WANG M B, et al. Chitosan microspheres/nano-hydroxyapatite/collagen/polylactide composite[J]. Acta Materiae Compositae Sinica,2009,26(2):143-148(in Chinese). doi: 10.3321/j.issn:1000-3851.2009.02.025
    [64] SUMATHRA M, MUNUSAMY M A, ALARFAJ A A, et al. Osteoblast response to vitamin D3 loaded cellulose enriched hydroxyapatite mesoporous silica nanoparticles compo-site[J]. Biomedicine & Pharmacotherapy,2018,103:858-868.
    [65] SUMATHRA M, SADASIVUNI K K, KUMAR S S, et al. Cisplatin-loaded graphene oxide/chitosan/hydroxyapatite composite as a promising tool for osteosarcoma-affected bone regeneration[J]. ACS Omega,2018,3(11):14620-14633. doi: 10.1021/acsomega.8b02090
  • 加载中
图(10)
计量
  • 文章访问数:  2846
  • HTML全文浏览量:  707
  • PDF下载量:  266
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-06-22
  • 录用日期:  2020-08-13
  • 网络出版日期:  2020-08-14
  • 刊出日期:  2020-12-15

目录

    /

    返回文章
    返回